Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies

被引:18
作者
Johnson, Derek R. [1 ]
Galanis, Evanthia [2 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Mol Med, Div Med Oncol, Dept Oncol, Rochester, MN USA
关键词
RANDOMIZED PHASE-III; NEWLY-DIAGNOSED GLIOBLASTOMA; SINGLE-AGENT BEVACIZUMAB; DOSE-DENSE TEMOZOLOMIDE; CARMUSTINE BCNU WAFERS; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; INTRAARTERIAL ACNU; LOCAL CHEMOTHERAPY; RADIATION-THERAPY;
D O I
10.1053/j.seminoncol.2014.06.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-grade astrocytomas are aggressive and incurable primary brain tumors. Radiation therapy with concurrent and adjuvant temozolomide chemotherapy is the standard-of-care treatment for newly diagnosed glioblastoma, while the role of chemotherapy in the initial treatment of anaplastic astrocytoma is evolving. Currently available medical options at tumor progression include further cytotoxic therapy and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab. Investigational treatments including numerous molecularly targeted agents and immunotherapeutic approaches are currently being evaluated. Significant future progress will require better understanding and exploitation of the molecular heterogeneity within high-grade astrocytoma, as well as innovative trial designs to evaluate efficiently targeted therapies in the subsets of patients in which they are most likely to be effective. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:511 / 522
页数:12
相关论文
共 83 条
  • [1] Afra D, 2002, LANCET, V359, P1011
  • [2] Alliance for Clinical Trials in Oncology, 2000, RAD THER CONC ADJ TE
  • [3] [Anonymous], ASCO M
  • [4] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
    Batchelor, Tracy T.
    Mulholland, Paul
    Neyns, Bart
    Nabors, L. Burt
    Campone, Mario
    Wick, Antje
    Mason, Warren
    Mikkelsen, Tom
    Phuphanich, Surasak
    Ashby, Lynn S.
    DeGroot, John
    Gattamaneni, Rao
    Cher, Lawrence
    Rosenthal, Mark
    Payer, Franz
    Juergensmeier, Juliane M.
    Jain, Rakesh K.
    Sorensen, A. Gregory
    Xu, John
    Liu, Qi
    van den Bent, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3212 - 3218
  • [5] Pseudoprogression and pseudoresponse in the treatment of gliomas
    Brandsma, Dieta
    van den Bent, Martin J.
    [J]. CURRENT OPINION IN NEUROLOGY, 2009, 22 (06) : 633 - 638
  • [6] Intra-Arterial Chemotherapy for Malignant Gliomas: a Critical Analysis
    Burkhardt, J-K.
    Riina, H. A.
    Shin, B. J.
    Moliterno, J. A.
    Hofstetter, C. P.
    Boockvar, J. A.
    [J]. INTERVENTIONAL NEURORADIOLOGY, 2011, 17 (03): : 286 - 295
  • [7] Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
    Cairncross, Gregory
    Wang, Meihua
    Shaw, Edward
    Jenkins, Robert
    Brachman, David
    Buckner, Jan
    Fink, Karen
    Souhami, Luis
    Laperriere, Normand
    Curran, Walter
    Mehta, Minesh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) : 337 - 343
  • [8] Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
    Cairncross, J. Gregory
    Wang, Meihua
    Jenkins, Robert B.
    Shaw, Edward G.
    Giannini, Caterina
    Brachman, David G.
    Buckner, Jan C.
    Fink, Karen L.
    Souhami, Luis
    Laperriere, Normand J.
    Huse, Jason T.
    Mehta, Minesh P.
    Curran, Walter J., Jr.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 783 - +
  • [9] Celldex Therapeutics C, 2000, PHAS 3 STUD RIND GM
  • [10] The potential role and application of PARP inhibitors in cancer treatment
    Chalmers, Anthony J.
    [J]. BRITISH MEDICAL BULLETIN, 2009, 89 (01) : 23 - 40